Tremelimumab

被引：16

作者：

不详

机构：

来源：

Drugs in R & D | 2010年 / 10卷 / 2期

关键词：

Breast-cancer; Colorectal-cancer; Gastrointestinal-; cancer; Malignant-melanoma; Pancreatic-cancer; Pfizer; Prostate-cancer; Research-and-development; treatment; Tremelimumab; therapeutic use;

D O I：

10.2165/11584530-000000000-00000

中图分类号：

学科分类号：

摘要：

Tremelimumab (CP 675206; CP-675; CP-675,206; CP-675206; Ticilimumab) is a fully human IgG2 anitbody, which is directed against human cytotoxic T lymphocyte-associated antigen 4 (CTLA4). It is being developed by Pfizer for the treatment of various cancers. It is currently in worldwide phase III development for malignant melanoma, phase II development for colorectal cancer, gastrointestinal cancer, gynecological cancer, and non-small cell lung cancer in the US and other countries, and is also being investigated for prostate, breast, and pancreatic cancer in various countries. This review discusses the key development milestones and therapeutic trials of this drug. © 2010 Adis Data Information BV. All rights reserved.

引用

页码：123 / 132

页数：9

共 16 条

[1]

Debiopharm Group. Pfizer and Debiopharm Collaborate to Co-develop Investigational Compound Tremelimumab (CP-675, 206) in Advanced Melanoma, (2010)

[2]

Medarex Announces Major Antibody Strategic Alliance with Pfizer, (2004)

[3]

Chung K.Y., Gore I., Fong L., Et al., A phase II study of the anti-CTLA4 monoclonal antibody, CP-675, 206, in patients with refractory metastatic adenocarcinoma of the colon or rectum, J. Clin. Oncol., 25, 18 SUPPL., (2007)

[4]

Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma, (2008)

[5]

Pfizer Fourth-quarter and Full-year 2005 Financial Results Reflect Operating and Financial Strength, (2006)

[6]

Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009, (2007)

[7]

Tarhini A.A., Moschos S.S., Schlesselman J.J., Et al., Phase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma, 44th Annual Meeting of the American Society of Clinical Oncology, (2008)

[8]

Patients Who Took Investigational Melanoma Compound CP 675206 Showed Favorable Survival Outcomes, (2007)

[9]

Zatloukal P., Heo D.S., Park K., Et al., Randomized phase II clinical trial comparing tremelimumab (CP-675, 206) with best supportive care following first-line platinum-based therapy in patients with advanced non-small cell lung cancer, 45th Annual Meeting of the American Society of Clinical Oncology, (2009)

[10]

Camacho L.H., Ribas A., Glaspy J.A., Et al., Phase I clinical trial of anti-CTLA4 human monoclonal antibody CP-675206 in patients (pts) with advanced solid malignancies, 40th Annual Meeting of the American Society of Clinical Oncology, 164, (2004)

← 1 2 →